Scancell to Join Nasdaq Stock Market
Biotech company Scancell will now trade on Nasdaq after a new company deal.
Scancell, a cancer drug company, is joining the Nasdaq stock market. This move follows a deal with another company, Neuphoria. The agreement lets Scancell become a publicly traded company.
Neuphoria faced problems last year. It stopped working on its anxiety medicine. This left its investors looking for a solution. The deal with Scancell gives those investors a way out.
Scancell uses a special method called ImmunoBody. This method helps the body fight cancer. Its drugs aim to train the immune system. Now, more investors can support this important work.
This deal means more eyes on Scancell's cancer treatments. It brings new hope for patients and investors. It shows companies can find new paths forward, even when facing trouble.
Source: FierceBiotech
More from Biotech
